Keros Therapeutics, Inc. (KROS) stock forecast and price target
Price $10.30 · data as of November 13, 2026
12-month price target
Average target$19.83
Upside / downside+92.6%
Analysts6
ConsensusBuy
Low $16.00Average $19.83High $25.00
Gold marker: average target · white marker: today’s price ($10.30)
Analyst ratings
Strong buy 0Buy 4Hold 3Sell 0Strong sell 0
Earnings and revenue estimates
| Period | EPS estimate | EPS growth | Revenue estimate |
|---|---|---|---|
| Current fiscal year ends December 31, 2026 | $-3.35 | −245.7% | $41M |
| Next fiscal year ends December 31, 2027 | $-5.96 | −78.0% | $14M |
| Next quarter ends December 31, 2026 | $-1.41 | −63.9% | $428570 |
| Quarter after ends March 31, 2027 | $-1.51 | −24.8% | $0 |
Consensus of the analysts covering Keros Therapeutics, updated daily. In the last 30 days 1 estimates were raised and 0 lowered.
Frequently asked questions
What is the Keros Therapeutics stock price target?
The average 12-month target from 6 analysts is $19.83, 92.6% above the current price of $10.30 Targets range from $16.00 to $25.00.
Is Keros Therapeutics a buy according to analysts?
The consensus rating is “Buy” (4 buy, 3 hold). Ratings are opinions, not guarantees; this is not investment advice.
How much is Keros Therapeutics expected to earn?
Analysts expect EPS of $-3.35 for the fiscal year ending December 31, 2026 and $-5.96 the year after.
Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.